Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics, Inc. (Nasdaq: OTLK) said on Oct. 09, 2026 that it named Greg DiPasquale Chief Commercial Officer, promoting the executive who joined the company in December 2025 as Head of Commercial for LYTENAVA™ (bevacizumab-vikg). The company said it expects to make LYTENAVA, which it describes as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD), available to eligible US patients before the end of 2026. DiPasquale carries more than 30 years of commercial leadership experience, nearly two decades of it in eye care.

Context — Why Does the LYTENAVA Commercial Build Matter Now?

Outlook Therapeutics is converting a regulatory approval into a commercial operation, and the CCO appointment is the staffing step that precedes a US launch the company dates to before the end of 2026. The report gives no prior-period revenue, no launch-cost guidance and no headcount target for the commercial build, so the scale of the spend behind that date is not disclosed.

What the report does supply is a precedent: LYTENAVA will be the fifth retina launch of DiPasquale's career. The company names the prior four — BEOVU® (brolucizumab) at Novartis, the EYLEA® prefilled syringe and EYLEA® HD at Regeneron, and the TRIESENCE® relaunch at Harrow. Each was a branded retina product taken to the same specialist audience LYTENAVA now targets.

That matters because retina commercialization is a specialist-selling exercise rather than a primary-care one. The report states DiPasquale built the US sales organization for Novartis's newly formed Retina Division from the ground up and led the October 2019 BEOVU launch, and that he later ran national EYLEA sales at Regeneron across the product's largest indications and its national strategic accounts inside a portfolio generating approximately $6 billion in annual revenue.

Outlook has already begun selling LYTENAVA outside the US. The company said it commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria and the UK as a wet AMD treatment, and that the product holds European Commission and MHRA Marketing Authorizations. In certain EU member states, the report notes, LYTENAVA must receive pricing and reimbursement approval before it can be sold.

The report provides no US pricing, no payer-coverage commitments and no launch-quarter revenue target. Those are the inputs a commercial organization would normally publish alongside a launch date, and their absence leaves the US revenue trajectory unquantified at this stage.

Data — What the LYTENAVA Numbers Show

The report's hard figures are dates and authorizations rather than financials. DiPasquale joined in December 2025; the CCO announcement is dated Oct. 09, 2026; the stated US availability window is before the end of 2026; the BEOVU launch he led occurred in October 2019. LYTENAVA is the fifth retina launch of his career, per the company.

Item	Report figure
DiPasquale start at Outlook	December 2025
CCO announcement date	Oct. 09, 2026
Stated US availability	Before end of 2026
Retina launches in career	Fifth
Regeneron portfolio cited	~$6 billion annual revenue
Commercial experience	More than 30 years

The only dollar figure the report attaches to DiPasquale's background is the approximately $6 billion in annual revenue for the Regeneron portfolio in which he led national EYLEA sales. That is a prior-employer figure, not an Outlook revenue projection, and the company gives no comparable number for LYTENAVA.

The safety profile disclosed in the report is the clinical data point investors can weigh. The most common adverse reactions at 1% or greater in patients receiving LYTENAVA were conjunctival hemorrhage at 4%, eye pain at 2% and vitreous floaters at 2%. LYTENAVA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to bevacizumab products or any ingredient in LYTENAVA.

The company also flagged post-injection increases in intraocular pressure observed up to 60 minutes after administration, and a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors, though it said the rate observed in LYTENAVA clinical trials was low.

Analysis — Which Tickers and Sectors Are Exposed?

OTLK is the direct exposure. The equity case now rests on execution against a launch date the company itself set, and the CCO hire is the clearest signal yet that the commercial infrastructure is being assembled rather than outsourced. The report states DiPasquale will lead market access, commercial operations, marketing, sales and reimbursement — the five functions that determine whether a specialist product reaches physicians and gets paid for.

The reimbursement function is the one to watch. The report notes that in certain EU member states LYTENAVA must clear pricing and reimbursement approval before sale, which establishes that payer negotiation is a gating step in this product's commercial model. The report does not say whether US payer coverage is already secured.

The competitive read sits with the branded anti-VEGF franchise the report names. DiPasquale's resume includes the EYLEA prefilled syringe, EYLEA HD and BEOVU, so the launch playbook he is expected to run was built against the incumbent branded agents. The report does not name any competitor's current market share or pricing, so no share-shift estimate is supportable from this document.

The counter-argument is straightforward: a launch date is an expectation, not a completed event. The report frames US availability as a plan, and the forward-looking section lists regulatory timing, market adoption and revenue generation as risks. A single commercial hire does not de-risk payer coverage, physician adoption or manufacturing scale.

On positioning, the report offers no ownership data, no short interest and no analyst estimates, so flow direction cannot be characterized from it. What can be said is that the news is a company-confirmed operational milestone ahead of a stated launch window, which places the burden of proof on the coming quarters.

Outlook — What to Watch Before the US Launch

The first checkpoint is whether Outlook confirms US commercial availability within its stated before-end-of-2026 window; the report gives no more specific date. The second is payer and reimbursement progress in the US, which the report does not address and which the EU experience shows can gate sales. The third is whether the company discloses pricing or launch economics, neither of which appears in this announcement.

Investors should also track the European rollout the company said has commenced in Germany, Austria and the UK, since that provides the earliest read on real-world adoption of the ophthalmic bevacizumab formulation. The report gives no European revenue figures, so any comparison to US expectations would be unsupported.

The report names no price levels, no moving averages and no analyst targets for OTLK, so there are no technical thresholds to cite here. The operative variable is the calendar: the company's own before-end-of-2026 window is the deadline against which execution will be judged.

Frequently Asked Questions

What does Greg DiPasquale's promotion mean for Outlook Therapeutics investors?

It consolidates commercial responsibility under one executive ahead of a stated US launch. The company said DiPasquale will lead market access, commercial operations, marketing, sales and reimbursement. He joined in December 2025 as Head of Commercial for LYTENAVA, so the promotion formalizes a role he already held rather than introducing an outside hire. The report does not disclose his compensation or any change to the commercial headcount plan.

Is LYTENAVA already available in the United States?

Not according to the report. The company said it is preparing to make LYTENAVA available to eligible US patients before the end of 2026, which frames US availability as a plan rather than a completed launch. Outlook has, however, commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria and the UK. The report notes that in certain EU member states the product must first receive pricing and reimbursement approval.